FLT4

Gene

fms related receptor tyrosine kinase 4

HGNCHGNC:3767 EnsemblENSG00000037280 NCBI Gene2324

Locus: gene with protein productLocation: 5q35.3

Encodes

via encodes

The protein product this gene encodes, reached through the canonical GENE→PROTEIN (encodes) relation. Its biology, drugs, indications, trials and therapeutic evidence live on the protein's own page.

Vascular endothelial growth factor receptor 3P35916

Protein · therapeutic target

Clinically validated target · 18 approved medicines against this target

Explore protein biology & therapeutics

Also known as

Symbols and names change; identity (the HGNC ID) does not. Previous and alternative forms are kept distinct.

Also known asVEGFR3 · PCL · VEGFR-3

View full nomenclature history (9)

Alias symbolsVEGFR3, PCL, VEGFR-3

Previous namesfms-related tyrosine kinase 4, fms related tyrosine kinase 4

Alias namesFeline McDonough Sarcoma (FMS)-like tyrosine kinase 4, vascular endothelial growth factor receptor 3, VEGF receptor-3, primary congenital lymphedema

Associated diseases

via associated_with

Diseases linked to this gene through the canonical GENE→DISEASE (associated_with) relation, drawn from Open Targets' top-ranked associations by overall score — not the full association set. Disease-level detail lives on each disease's own page.

Lymphatic malformation 1

Congenital heart defects, multiple types, 7

Milroy disease

Carcinoma, Hepatocellular

Gastrointestinal Stromal Tumors

Carcinoma, Non-Small-Cell Lung

Capillary infantile hemangioma

Neoplasms

Carcinoma, Renal Cell

Thyroid gland carcinoma

Drawn from Open Targets’ top 10 associations by overall score for this gene — the subset resolved to a canonical disease. Lower-ranked associations, and diseases not yet canonicalised, are not shown.

Gene family

HGNC gene-group membership.

I-set domain containingVEGF receptor tyrosine kinase family

Provenance

HGNCCanonical human gene identity from HGNC (release 2026-07-07), updated 2023-01-20.

Open TargetsGene–disease associations from the Open Targets Platform.